There is nothing like a global pandemic to motivate the need for improved respiratory treatments and mucosal vaccines. Stimulated by the COVID-19 pandemic, pulmonary aerosol drug delivery has seen a flourish of activity, building on the prior decades of innovation in particle engineering, inhaler device technologies, and clinical understanding. As such, the field has expanded into new directions and is working toward the efficient delivery of increasingly complex cargos to address a wider range of respiratory diseases. This review seeks to highlight recent innovations in approaches to personalize inhalation drug delivery, deliver complex cargos, and diversify the targets treated and prevented through pulmonary drug delivery. We aim to inform readers of the emerging efforts within the field and predict where future breakthroughs are expected to impact the treatment of respiratory diseases.Expected final online publication date for the Annual Review of Biomedical Engineering, Volume 26 is May 2024. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.

中文翻译：

---

气溶胶肺部给药的最新进展：新技术、新货物和新靶点

没有什么比全球大流行更能激发对改进呼吸道治疗和粘膜疫苗的需求了。受新冠肺炎 (COVID-19) 大流行的刺激，肺气雾剂药物输送活动蓬勃发展，其基础是过去几十年在颗粒工程、吸入器设备技术和临床理解方面的创新。因此，该领域已经扩展到新的方向，并致力于有效地运送日益复杂的货物，以解决更广泛的呼吸道疾病。本综述旨在强调个性化吸入药物输送、输送复杂货物以及通过肺部药物输送治疗和预防的目标多样化的方法的最新创新。我们的目标是让读者了解该领域内的新兴努力，并预测未来的突破预计将影响呼吸系统疾病的治疗。《生物医学工程年度评论》第 26 卷的预计最终在线出版日期为 2024 年 5 月。请参阅 http: //www.annualreviews.org/page/journal/pubdates 了解修订后的估计。